Patent · US Active

FcRn-targeted mucosal vaccination against RSV

US12138306B2 · kind B2 · utility

0Cited by
2References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 3, 2022
Grant dateNov 12, 2024
Priority date—
Expiry dateJun 3, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/18571
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Disclosed are nucleic acid sequences capable of encoding peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Also disclosed are methods for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by FcRn; a modified pre-fusion RSV F protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.